

ABIOMED Launches New Clinical Education and Service Program Designed to Improve Recovery

Program features interactive training course, available for preview at www.abiomed.com

DANVERS, Mass. and Louisville, Co (January 4, 2005) – ABIOMED, Inc. (NASDAQ: ABMD) a manufacturer of products for circulatory care and support, today announced the launch of a new education and service program designed to promote heart recovery. The program combines clinical training, web-based education, process improvement, and field service. "By providing clinical support and education on best practices including early implantation, time on support, and reducing bleeding, we can help our hospitals improve outcomes," said Michael R. Minogue, CEO and President of ABIOMED. "Our goal is to give our customers the tools they need to help acute patients recover and go home with their own hearts."

The program includes web-based learning modules developed by eTrinsic that will enable clinical teams to be trained on the AB5000 and BVS 5000 using an interactive course that simulates the clinical experience. "By combining leading edge educational process and technology, the course simulates important aspects of this procedure so that clinicians and other healthcare professionals can now learn in a risk-free environment that is both compelling and realistic. Our goal is improved outcomes, and we are pleased to have participated in this project with ABIOMED," said Jacques Devaud, CEO and President of eTrinsic. The course will also share the techniques and practices that have been shown to promote survival and recovery at ABIOMED's top centers. For instance, at the top 20% of centers in the company's installed base, the survival rate for patients implanted with ABIOMED's Ventricular Assist Devices (VADs) is greater than 50%.

The courses are accredited and healthcare providers that successfully complete the modules are eligible to receive continuing education credits. Additional clinical modules on ABIOMED's products and a general program designed to educate patients and families will be available in the near future.

In addition, ABIOMED is offering its service program customers an on-site productivity and best practices consult, a reimbursement kit, and a media and marketing kit. The media and marketing kit will provide hospitals with the tools necessary to educate audiences including referring cardiologists, VAD coordinators, patients, families, and health reporters on the addition of this life-saving technology. The Best Practices consult will include an analysis of both clinical and administrative practices, and offer solutions to optimize reimbursement, improve processes and enhance patient outcomes.

About eTrinsic

eTrinsic develops revolutionary e-learning content using simulation and tracking technology, called True Learning Experiences™, for medical device and equipment, life science and healthcare organizations worldwide. eTrinsic's experience includes developing interactive courseware for end users including sales reps, physicians, clinicians, patients and customers, and working with medical device and equipment

manufacturers in all stages of product development. eTrinsic offers the True Learning Environment™ (TLE) learning management system (LMS) and the True Assessment System™ (TAS), a scalable server-side tracking system which validates true comprehension of course material by measuring user proficiency in solving a problem with a complex set of variables. Additional company information can be found at www.etrinsic.com.

About ABIOMED

Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED, which currently sells the BVS® 5000 Biventricular Support System and the AB5000™ Circulatory Support System, is the market leader in devices for the temporary support of patients with failing but potentially recoverable hearts. In September 2004, ABIOMED applied for initial FDA market approval for the AbioCor Implantable Replacement Heart to treat a defined subset of irreversible end-stage heart failure patients under a Humanitarian Device Exemption.

Media Contact:

Jacques Devaud
President & CEO
eTrinsic, Inc.
(303)-381-2325

Media Contact:

Andrea tenBroek
Communications Specialist
(978) 646-1815
mediarelations@abiomed.com

Investor Relations Contact:

Jane Petrino
Euro RSCG Life NRP
(212) 845-4274
jane.petrino@eurorscg.com